The Cancer Epigenetics Society is happy to announce the appointment of Dr. Owen A. O’Connor to the Editorial Board of Clinical Cancer Epigenetics.
Dr. O’Connor is Professor of Medicine and Experimental Therapeutics at Columbia University and Director of the Center for Lymphoid Malignancies at the Herbert Irving Comprehensive Cancer Center (New York, NY, USA). Dr. O’Connor’s work has had a major impact on the treatment and management of lymphoid malignancies with the FDA approval of several cancer drugs innovated or developed by Dr. O’Connor.
Join the Society today as a Professional (biomedical students & professionals) or Affiliate member (everyone else) by clicking on the Membership button!
Among the drugs now in use in clinical cancer practice developed under the leadership of Dr. O’Connor are Pralatrexate (used to treat relapsed or refractory peripheral T-cell lymphoma or PTCL), the proteasome inhibitor Bortezomib (used to treat mantle cell lymphoma), and the histone deacetylase inhibitor (HDACi) Vorinostat (Zolinza, used to treat cutaneous T-cell lymphoma or CTCL).
In addition to his academic responsibilities, Dr. O’Connor is co-founder and Director of Therasis, Inc., a company focused on oncology therapeutics in New York. In addition to Clinical Cancer Epigenetics, Dr. O’Connor is a Senior Editor of Clinical Cancer Research (AACR).
The Cancer Epigenetics Society is excited to have Dr. Owen O’Connor on the Clinical Cancer Epigenetics Editorial Board, and we very much look forward to working with him in establishing the highest possible standards in lymphoid cancer research and discovery (Cancer Epigenetics Society news, July 20, 2017).